Judgment of the General Court (Second Chamber) of 5 December 2018
Bristol-Myers Squibb Pharma EEIG v European Commission and European Medicines Agency
Medicinal products for human use — Orphan medicinal products — Decision withdrawing the designation of Elotuzumab as an orphan medicinal product — Decision that the designation criteria were no longer met — Marketing authorisation for the medicinal product for human use Empliciti (Elotuzumab) — Article 5(12)(b) of Regulation (EC) No 141/2000 — Article 5(8) of Regulation No 141/2000 — Obligation to state reasons
Case T-329/16
Reports of Cases
published in the electronic Reports of Cases (Court Reports - general - 'Information on unpublished decisions' section)
Links to the texts
|
Curia |
EUR-Lex |
Autres Liens |
Judgment
ECLI:EU:T:2018:878 |
|
|
|